Elsevier

Pharmacological Research

Volume 30, Issue 3, October–November 1994, Pages 187-228
Pharmacological Research

Re-evaluation of a biguanide, metformin: mechanism of action and tolerability

https://doi.org/10.1016/1043-6618(94)80104-5Get rights and content

Abstract

Metformin is a biguanide antidiabetic medication, that has been in use for over 30 years. Its mechanism of action, unknown until a few years ago, is now linked to an improved peripheral sensitivity to insulin, through a stimulated tissue glucose uptake by a transporter linked system. Interest in metformin has been revived by the recent observation of a specific activity of this agent on some of the major traits of the so called ‘polymetabolic syndrome’ (or ‘syndrome X’), characterized by: insulin resistance, hypertriglyceridemia, hypetension and reduced fibrinolytic activity. Metformin, in studies examining one or more of these, has been shown, possibly through its peripheral insulin sensitizing mechanism, to correct most of the major symptoms characterizing this insulin resistance syndrome. Metformin, similarly to the other biguanide phenformin, has been rated as potentially dangerous, because of the possible induction of lactic acidosis, in some cases with a fatal outcome. Metformin is, however, associated with a very low incidence of lactic acidosis because, differently from phenformin, it does not undergo liver metabolism and, as a consequence, there are no high-risk groups, displaying an impaired metabolic handling. In this review, in addition to an overall evaluation of the more recent data on the mechanism of action and clinical use of metformin, a detailed clinical analysis of all published cases of lactic acidosis is provided. These data indicate that the risk in metformin use is negligible, provided that care is taken when prescribing the drug to patients with suspected clinical risks of lactic acidosis.

References (139)

  • R.K. Gorus et al.

    In't Veld P, Gepts W, Pipeleers DG. Interaction of sulfonylureas with pancreatic β-cells A study with glyburide

    Diabetes

    (1988)
  • M.A. Pfeifer et al.

    Potentiation of insulin secretion to nonglucose stimuli in normal man by tolbutamide

    Diabetes

    (1980)
  • L.C. Groop et al.

    Secondary failure to treatment with oral antidiabetic agents in non-insulin dependent diabetes

    Diabetes Care

    (1986)
  • D.C. Simonson

    Effects of glyburide on in vivo insulin-mediated glucose disposal

    Am J Med

    (1990)
  • G.M. Reaven

    Role of insulin resistance in human disease

    Diabetes

    (1988)
  • J.M. Flack et al.

    Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia

    Am J Med

    (1991)
  • E.E. Slater

    Insulin resistance and hypertension

    Hypertension

    (1991)
  • C.J. Bailey

    Metformin revisited: its actions and indications for use

    Diabetic Med

    (1988)
  • R. Nosadini et al.

    Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type 11 diabetes

    Diabetes Care

    (1987)
  • H. Leblanc et al.

    Combined continuous subcutaneous insulin infusion in 10 overweight insulin requiring diabetic patients

    Diabete Metab

    (1987)
  • H. Gin et al.

    Metformin reduces post-prandial insulin needs in type I (insulin-dependent) diabetic patients: assessment by the artificial pancreas

    Diabetologia

    (1982)
  • S.A. Wake et al.

    Effects of exercise training and dietary manipulation on insulin-regulatable glucose-transporter mRNA in rat muscle

    Diabetes

    (1991)
  • E.I.M. Widen et al.

    Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM

    Diabetes

    (1992)
  • A. Klip et al.

    Stimulation of hexose transport by metformin in L6 muscle cells in culture

    Endocrinology

    (1992)
  • V. Sarabia et al.

    Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin

    J Clin Invest

    (1992)
  • H.S. Hundal et al.

    Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells

    Endocrinology

    (1992)
  • I.J. Kozka et al.

    Metformin blocks downregulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes

    Diabetes

    (1993)
  • G.M. Reaven et al.

    Combined metformin-sulphylurea treatment of patients with non insulindependent diabetes in fair to poor glycemic control

    J Clin Endocrinol Metab

    (1992)
  • K. Landin et al.

    Treating insulin resistance in hypertension with metformin reduces blood pressure and metabolic risk factors

    J Int Med

    (1991)
  • S. Bertuglia et al.

    Effects of metformin on arterial vasomotion in normal and diabetic Syrian hamsters

    Diabete Metab

    (1988)
  • C.R. Sirtori et al.

    Metformin improves peripheral vascular flow in non hyperlipidemic patients with arterial disease

    J Cardiovasc Pharmacol

    (1984)
  • I. Juhan-Vague et al.

    Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and the acute phase response

    Arteriosclerosis

    (1989)
  • P. Vague et al.

    Metformin decreases the elevated levels of plasminogen activator inhibitor, plasma insulin and triglyceride in non diabetic obese subjects

    Thromb Haemost

    (1987)
  • G. Bari Kolata

    The phenformin ban: is the drug an imminent hazard?

    Science

    (1979)
  • G. Schafer

    Guanidines and biguanides

    Pharmacol Ther

    (1979)
  • E. Bisisio et al.

    Defective hdyroxylation of phenformin as a determinant of drug toxicity

    Diabetes

    (1981)
  • R. Beckmann

    Über die Resorption and den biologischen Abbau von 1-(β-phenäthyl)-biguanid (Phenformin)

    Diabetologia

    (1967)
  • C. Heuclin et al.

    Acidose lactique et thérapeutique par biguanides

    Journ Annu Diabetol Hotel-Dieu

    (1975)
  • R.R. Shah et al.

    The genetic control of phenformin 4-hydroxylation

    J Med Genet

    (1985)
  • M. Eichelbaum

    Polymorphic drug oxidation in humans

  • A.C. Gough et al.

    Identification of the primary gene defect at the cytochrome P450 CYP2D locus

    Nature

    (1990)
  • D.A. Price-Evans et al.

    A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population

    J Med Genet

    (1980)
  • N.M. Woolhouse et al.

    Dissociation of coregulatory control of debrisoquine/phenformin and sparteine oxidation in Ghanaians

    Clin Pharmacol Ther

    (1985)
  • C.R. Sirtori et al.

    Disposition of metformin (N,N-dimethylbiguanide) in man

    Clin Pharmacol Ther

    (1978)
  • D. Alkalay et al.

    Pharmacokinetics of phenformin in man

    J Clin Pharmacol

    (1975)
  • N.S. Oates et al.

    Genetic polymorphism of phenformin 4hydroxylation

    Clin Pharmacol Ther

    (1982)
  • N.S. Oates et al.

    Influence of oxidation polymorphism on phenformin kinetics and dynamics

    Clin Pharmacol Ther

    (1983)
  • P. Pignard

    Dosage spectrophotometrique du N-N-dimethylbiguanide dans le sang et l'urine

    Ann Biol Clin (Paris)

    (1962)
  • W. Lintz et al.

    Butylbiguanide concentration in plasma, liver and intestine after intravenous and oral administration to man

    Eur J Clin Pharmacol

    (1974)
  • P.J. Pentikäinen et al.

    Pharmacokinetics of metformin after intravenous and oral administration to man

    Eur J Clin Pharmacol

    (1979)
  • Cited by (0)

    View full text